

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 23, 2003

BECTON, DICKINSON AND COMPANY

(Exact name of registrant as specified in its charter)

<TABLE>

<S>	<C>	<C>
New Jersey	001-4802	22-0760120
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

1 Becton Drive, Franklin Lakes, New Jersey 07417-1880

(Address of principal executive offices) (Zip Code)
</TABLE>

Registrant's telephone number, including area code (201) 847-6800

N/A

(Former name or former addresses if changed since last report.)

Item 5. Other Events and Regulation FD Disclosure.

On January 23, 2003 the Registrant announced in a press release its results for the first quarter ended December 31, 2002.

A copy of the press release is attached as Exhibit 99.1.

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit 99.1 Press release dated January 23, 2003
announcing the financial results for the
first quarter ended December 31, 2002.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Gary DeFazio

Gary DeFazio
Assistant Secretary

Date: January 23, 2003

2

INDEX TO EXHIBITS

<TABLE>
<CAPTION>

Exhibit Number -----	Description of Exhibits -----
<S> 99.1	<C> Press release issued January 23, 2003

</TABLE>

STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as.....'TM'

Contact:

- -----

Dean J. Paranicas/Investor Relations - 201-847-7102
Patricia A. Spinella/Investor Relations - 201-847-5453
Charles A. Borgognoni/Corporate Communications - 201-847-6651

BD ANNOUNCES RESULTS FOR FISCAL FIRST QUARTER

Franklin Lakes, NJ (January 23, 2003) - BD (Becton, Dickinson and Company) (NYSE: BDX) today reported revenues of \$1.052 billion for the fiscal first quarter ended December 31, 2002, an increase of 11 percent from the same period a year ago. At constant foreign exchange rates, revenues increased 9 percent.

"We are pleased with the Company's strong revenue growth in the quarter, paced by our BD Medical Systems and BD Clinical Laboratory Solutions segments that reflect contributions from several key areas - safety-engineered products, prefillable drug delivery devices and our BD ProbeTec ETTM diagnostic instrument platform," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "As we had forecast, BD Biosciences' first quarter revenues were slightly ahead of the prior year's quarter. This reflected the impact of factors unfavorably affecting sales of molecular biology reagents and flow cytometry instruments that we expect will continue through the second quarter, but which we anticipate will improve in the second half of the year."

"We are very excited about the launch of our new blood glucose monitoring products, the BD LogicTM Blood Glucose Monitor and the BD LatitudeTM Diabetes Management System," Mr. Ludwig added. "These products are among the most significant launches in the Company's history, and we believe their best-in-class performance characteristics, coupled with our strategic relationships with Medtronic, Inc. and Eli Lilly and Company, position us for success in the blood glucose monitoring market."

Diluted earnings per share and net income for the quarter were 43 cents and \$114 million, respectively. For the same period in fiscal 2002, diluted earnings per share and net income were 37 cents and \$100 million, respectively. Diluted earnings per share reflected, among other things, the benefit of approximately 2 cents related to favorable foreign exchange translation, particularly in Europe.

Segment Results

- -----

In the BD Medical Systems segment, worldwide revenues of \$572 million increased 14 percent in the quarter, driven by U.S. safety-engineered product sales of \$100 million, versus \$78 million in the prior year's quarter, and strong sales of prefillable drug delivery devices, which grew 30 percent to \$93 million. Consumer Healthcare products also posted strong growth in the quarter, based in part on a favorable comparison to 2002 in U.S. diabetes syringe sales. The overall growth rate in the segment was partly offset by reduced sales of certain conventional devices in the U.S. due to the transition to safety-engineered devices.

In the BD Clinical Laboratory Solutions segment, worldwide revenues increased 13 percent for the quarter to \$332 million. Revenue growth of 12 percent in the Preanalytical Solutions portion of the segment was due primarily to strong U.S. safety-engineered product sales, which were \$65 million, versus \$49 million in the prior year's quarter, and which were partly offset by reduced sales of certain conventional devices in the U.S. due to the transition to safety-engineered devices. Contributing to revenue growth of 13 percent in the Diagnostics Systems portion of the segment were strong sales of respiratory and flu diagnostic tests, especially in Japan, and worldwide sales of its molecular diagnostic platform, BD ProbeTec ETTM.

The BD Biosciences segment's worldwide revenues were slightly ahead of last year at \$148 million. These results reflected strong sales of flow cytometry reagents and immunology/cell biology (Pharmingen) reagents and Discovery Labware products. This growth was partly offset by sales of molecular biology (Clontech) reagents, which were below the prior year due to continued weakness in some portions of the molecular biology research market. In addition, as anticipated, flow cytometry instrument sales growth in the quarter was negatively impacted by a reduction in order backlog in fiscal 2002 resulting from order fulfillment and installation improvements. In addition, favorable reaction to the first quarter announcement of the new BD FACSAriaTM cell sorter caused some order postponement in anticipation of the availability of this new instrument later in the year.

Geographic Results

- -----

On a geographic basis, first quarter revenues in the U.S. increased 12 percent to \$557 million. Revenues outside the U.S. of \$494 million grew 10 percent, or 5 percent at constant foreign exchange rates. International revenues in the first quarter benefited from strong performance in Japan, offset in part by the effects of continuing unfavorable economic conditions in Latin America.

A conference call regarding BD's first quarter results and its expectations for the second quarter and full fiscal year will be broadcast live on BD's website at 8:30 a.m. EST Thursday, January 23, 2003. The conference call will be available for playback at 1-800-468-0320 (domestic) and 1-402-344-6805 (international) through the close of business on January 30, 2003.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2002, BD reported total revenues of \$4.033 billion.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding the Company's performance, including future revenues, products and income, or events or developments that the Company expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of the Company and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; the Company's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in the Company's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in the Company's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

BD's news releases can be found on its website at www.bd.com or through Business Wire at www.businesswire.com.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Three Months Ended December 31,		
	2002	2001	% Change
<S>	<C>	<C>	<C>
REVENUES	\$ 1,051,648	\$ 944,946	11.3
Cost of products sold	550,039	499,762	10.1
Selling and administrative	284,181	248,294	14.5
Research and development	59,845	55,237	8.3
TOTAL OPERATING COSTS AND EXPENSES	894,065	803,293	11.3
OPERATING INCOME	157,583	141,653	11.2
Interest expense, net	(8,633)	(9,571)	(9.8)
Other income (expense), net	84	(1,616)	NM

INCOME BEFORE INCOME TAXES	149,034	130,466	14.2
Income tax provision	35,396	30,793	14.9

NET INCOME	\$ 113,638	\$ 99,673	14.0

EARNINGS PER SHARE			
Basic	\$ 0.44	\$ 0.38	15.8
Diluted	\$ 0.43	\$ 0.37	16.2

AVERAGE SHARES OUTSTANDING			
Basic	255,286	259,192	
Diluted	263,081	270,172	

</TABLE>

NM - Not Meaningful

Page 1

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	Three Months Ended December 31,		
	2002	2001	% Change
	<C>	<C>	<C>
<S>			
BD MEDICAL SYSTEMS			

United States	\$ 296,426	\$ 250,902	18.1
International	275,211	252,128	9.2

TOTAL	\$ 571,637	\$ 503,030	13.6

BD CLINICAL LABORATORY SOLUTIONS			

United States	\$ 191,532	\$ 172,488	11.0
International	140,122	122,261	14.6

TOTAL	\$ 331,654	\$ 294,749	12.5

BD BIOSCIENCES			

United States	\$ 69,337	\$ 73,859	(6.1)*
International	79,020	73,308	7.8*

TOTAL	\$ 148,357	\$ 147,167	0.8

TOTAL REVENUES			

United States	\$ 557,295	\$ 497,249	12.1*
International	494,353	447,697	10.4*

TOTAL	\$ 1,051,648	\$ 944,946	11.3

* Prior year data reclassified to conform to current year presentation - see page 5

</TABLE>

Page 2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Three Months Ended December 31,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	United States		
	2002	2001	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
Medical Surgical	\$ 192,751	\$ 167,031	15.4 *
Consumer Health Care	75,496	61,292	23.2 *
Pharmaceutical Systems	21,527	16,283	32.2
Ophthalmic Systems	6,652	6,296	5.7
TOTAL	\$ 296,426	\$ 250,902	18.1
BD CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 101,023	\$ 87,315	15.7
Diagnostic Systems	90,509	85,173	6.3
TOTAL	\$ 191,532	\$ 172,488	11.0
BD BIOSCIENCES			
Discovery Labware	23,120	22,265	3.8
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	23,199	27,381	(15.3)
Molecular Biology Reagents	7,863	9,734	(19.2) *
Immunology/Cell Biology Reagents	15,155	14,479	4.7
Total Immunocytometry & Reagents	46,217	51,594	(10.4) *
TOTAL	\$ 69,337	\$ 73,859	(6.1) *
TOTAL UNITED STATES	\$ 557,295	\$ 497,249	12.1 *

</TABLE>

<TABLE>
<CAPTION>

	International		
	2002	2001	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			
Medical Surgical	\$ 152,768	\$ 145,964	4.7
Consumer Health Care	44,049	44,974	(2.1)
Pharmaceutical Systems	71,718	55,265	29.8
Ophthalmic Systems	6,676	5,925	12.7
TOTAL	\$ 275,211	\$ 252,128	9.2
BD CLINICAL LABORATORY SOLUTIONS			
Preanalytical Solutions	\$ 66,180	\$ 62,068	6.6
Diagnostic Systems	73,942	60,193	22.8
TOTAL	\$ 140,122	\$ 122,261	14.6
BD BIOSCIENCES			
Discovery Labware	18,755	15,776	18.9
Immunocytometry & Reagents:			
Flow Cytometry Instruments & Reagents	40,853	40,505	0.9
Molecular Biology Reagents	7,892	7,246	8.9 *
Immunology/Cell Biology Reagents	11,520	9,781	17.8

Total Immunocytometry & Reagents	60,265	57,532	4.8 *

TOTAL	\$ 79,020	\$ 73,308	7.8 *

TOTAL INTERNATIONAL	\$ 494,353	\$ 447,697	10.4 *

* Prior year data reclassified to conform to current year presentation - see page 5

</TABLE>

Page 3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND MAJOR PRODUCT GROUPS
Three Months Ended December 31, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	Total		
	2002	2001	% Change
<S>	<C>	<C>	<C>
BD MEDICAL SYSTEMS			

Medical Surgical	\$ 345,519	\$ 312,995	10.4 *
Consumer Health Care	119,545	106,266	12.5 *
Pharmaceutical Systems	93,245	71,548	30.3
Ophthalmic Systems	13,328	12,221	9.1

TOTAL	\$ 571,637	\$ 503,030	13.6

BD CLINICAL LABORATORY SOLUTIONS			

Preanalytical Solutions	\$ 167,203	\$ 149,383	11.9
Diagnostic Systems	164,451	145,366	13.1

TOTAL	\$ 331,654	\$ 294,749	12.5

BD BIOSCIENCES			

Discovery Labware	41,875	38,041	10.1
Immunocytometry & Reagents:			
Flow Cytometry Instruments			
& Reagents	64,052	67,886	(5.6)
Molecular Biology Reagents	15,755	16,980	(7.2)
Immunology/Cell Biology Reagents	26,675	24,260	10.0

Total Immunocytometry & Reagents	106,482	109,126	(2.4)

TOTAL	\$ 148,357	\$ 147,167	0.8

TOTAL REVENUES	\$ 1,051,648	\$ 944,946	11.3

</TABLE>

<TABLE>
<CAPTION>

	FX Neutral % Growth	
	International	Total
<S>	<C>	<C>
BD MEDICAL SYSTEMS		

Medical Surgical	1.0	8.7
Consumer Health Care	(5.9)	10.9
Pharmaceutical Systems	20.4	23.1
Ophthalmic Systems	5.3	5.5

TOTAL	4.1	11.1
BD CLINICAL LABORATORY SOLUTIONS		
Preanalytical Solutions	1.0	9.6
Diagnostic Systems	18.6	11.4
TOTAL	9.6	10.5
BD BIOSCIENCES		
Discovery Labware	13.8	8.0
Immunocytometry & Reagents:		
Flow Cytometry Instruments & Reagents	(5.2)	(9.3)
Molecular Biology Reagents	4.3	(9.2)
Immunology/Cell Biology Reagents	10.4	7.0
Total Immunocytometry & Reagents	(1.4)	(5.6)
TOTAL	1.9	(2.1)
TOTAL	5.2	8.8

* Prior year data reclassified to conform to current year presentation - see page 5

</TABLE>

Page 4

BECTON DICKINSON AND COMPANY
IMPACT OF RECLASSIFICATIONS TO FISCAL 2002 REVENUES
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	Fiscal 2002 Revenues

<S>	
BD BIOSCIENCES SEGMENT	
Molecular Biology Reagents - US to International	
Quarter 1	\$ 2,841
Quarter 2	4,304
Quarter 3	3,430
Quarter 4	4,044
Total Year	\$14,619
BD MEDICAL SYSTEMS SEGMENT	
Medical Surgical to Consumer Health Care - US to US	
Quarter 1	\$ 2,523
Quarter 2	3,020
Quarter 3	3,446
Quarter 4	4,157
Total Year	\$13,146

</TABLE>

Page 5